SHR-2004
Unknown / undisclosed
Evidence outlook · registrational
Venous Thromboembolism: registrational trials complete
Its supporting mid-stage studies have completed. Its registrational studies have completed. Check News and the registry record for topline outcomes.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
Other Factor XI drugs
Cenvacibart, Gruticibart, SRSD107, Amrecibart. Compare all 5 Factor XI drugs
4 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Venous Thromboembolism: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| SHR-2004: this drug | Phase 3 | Undisclosed | Factor XI | not yet graded | No reviewed efficacy summary in this indication | |
| Cenvacibart | Phase 3 | Monoclonal antibody | Factor XI | not yet graded | No reviewed efficacy summary in this indication | |
| Gruticibart | Phase 2(overall) | Monoclonal antibody | Factor XI | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| SRSD107 | Phase 2 | RNA / oligonucleotide | Factor XI | not yet graded | No reviewed efficacy summary in this indication | |
| Amrecibart | Phase 1(overall) | Monoclonal antibody | Factor XI | not yet graded(overall) | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.